Evolution of the Average Target: NOV Inc.

Evolution of the Average Target - NOV Inc.

Evolution of the Target Price: NOV Inc.

Evolution of the Target Price - NOV Inc.

Changes in Analyst Recommendations: NOV Inc.

a1477d9b2a6717ab61432.VFX4XIv9PREr90MRAcMyYz9kNGbp62my3cRtD2wVt7Y.ZxOfOuCMSV9npDJwNoZlKVsoXSistCj5jrBbVQZN9e45JI0d6pNlRRm8cw~56d2c2d3cddfa6c256c777560cf57f80
05/06 NOV Shares Rise After Capital One Upgrade MT
04/06 Capital One Upgrades NOV to Overweight From Equal Weight, Adjusts Price Target to $26 From $25 MT
30/04 Zephirin Cuts Price Target on NOV to $17 From $18, Keeps Hold Rating, Medium Risk MT
29/04 RBC Lifts Price Target on NOV to $22 From $21, Keeps Sector Perform Rating MT
14/04 NOV Offers Upside From Improved Offshore and Short-Cycle Activity but Better Alternatives Exist, RBC Says MT
14/04 RBC Downgrades NOV to Sector Perform From Outperform, Keeps $21 Price Target MT
14/04 Analyst recommendations: Biogen, Ford, Ge Vernova, Booking, Comcast… Zonebourse
23/02 Zephirin Downgrades NOV to Hold From Buy, Lifts Price Target to $18 From $17, Keeps Medium Risk MT
12/02 Analyst recommendations: Pfizer, Applovin, Biogen, Hilton, Snap… Zonebourse
04/02 Barclays Upgrades NOV to Equalweight From Underweight, Raises Price Target to $20 From $15 MT
04/02 Analyst recommendations: Booking, PayPal, Fedex, Gartner, Lockheed Martin…. Zonebourse
15/01 RBC Capital Adjusts NOV Price Target to $21 From $19, Maintains Outperform Rating MT
14/01 Analyst recommendations: Rivian, Applied Materials, Coinbase, Intel, Spotify… Zonebourse
20/11 Zephirin Lowers Price Target on NOV to $16 From $17, Keeps Buy Rating MT
29/25/29 RBC Raises Price Target on NOV to $19 From $17, Keeps Outperform Rating MT
09/25/09 RBC Lowers Price Target on NOV to $17 From $18, Keeps Outperform Rating MT
30/25/30 RBC Cuts Price Target on NOV to $18 From $19, Keeps Outperform Rating MT
29/25/29 NOV's Q2 revenue falls but beats expectations RE
15/25/15 Zephirin Cuts Price Target on NOV to $17 From $19, Keeps Buy Rating MT
30/25/30 RBC Trims Price Target on NOV to $19 From $20, Keeps Outperform Rating MT
24/25/24 Analyst recommendations: General Mills, Ulta Beauty, Micron Technology, RH… Zonebourse
24/25/24 RBC Upgrades NOV to Outperform From Sector Perform, Maintains $22 Price Target MT
06/25/06 RBC Raises Price Target on NOV to $22 From $21, Keeps Sector Perform Rating MT
15/25/15 Evercore ISI Downgrades NOV to In Line From Outperform, Adjusts Price Target to $18 From $25 MT
06/25/06 Seaport Downgrades NOV to Neutral From Buy MT

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
+14.87%
+16.08%
+26.89%
+5.55%
+20.76%
+11.7%
+115.14%
+10.9%
+12.07%
+20.47%
Average +25.44%
Weighted average by Cap. +21.92%


Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
20
Last Close Price
19.29USD
Average target price
22.16USD
Spread / Average Target
+14.87%
High Price Target
26.00USD
Spread / Highest target
+34.78%
Low Price Target
17.00USD
Spread / Lowest Target
-11.87%

Analyst Consensus Detail

Analyst consensus - NOV Inc.

Consensus revision (last 18 months)

Consensus revision (last 18 months) - NOV Inc.
Trader
Investor
Global
Quality
ESG MSCI
AA
MarketScreener Ratings - NOV Inc.